Nasdaq stocks posting largest percentage decreases
AP - Thu Sep 25, 12:24PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Regulatory Approvals, Senior Notes Redemption, and Technical Updates - Research Reports on Tekmira, Regeneron, Valeant, Teva and United Therapeutics
PR Newswire - Thu Sep 25, 8:20AM CDT
Today, Analysts Review released its research reports regarding Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and United Therapeutics Corporation (NASDAQ: UTHR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6765-100free.
Critical Alerts For Tekmira Pharmaceuticals, Herbalife, Alcoa, Actavis and Twitter Released By InvestorsObserver
PR Newswire - Wed Sep 24, 9:37AM CDT
InvestorsObserver issues critical PriceWatch Alerts for TKMR, HLF, AA, ACT and TWTR.
'Fast Money' Recap: How to Play the Falling Market
at The Street - Wed Sep 24, 4:00AM CDT
The trading panel discussed whether the Alibaba IPO is affecting the markets and whether Apple shares will decline.
Tekmira Joins International Consortium to Conduct Clinical Trials of Ebola Virus Therapeutics in West Africa
GlobeNewswire - Tue Sep 23, 5:09AM CDT
Consortium Receives £3.2 Million Funding From Wellcome Trust
Tekmira Experimental Ebola Drug Used to Treat Stricken U.S. Doctor
at The Street - Mon Sep 22, 6:48PM CDT
Ebola patient Dr. Rick Sacra received treatment with Tekmira Pharmaceuticals' experimental ebola therapy TKM-Ebola for seven days, Nebraska Medical Center confirmed.
Why Tekmira Pharmaceuticals (TKMR) Stock Is Spiking Today
at The Street - Mon Sep 22, 11:02AM CDT
Tekmira Pharmaceuticals (TKMR) shares are up double digits after the company announced that it received regulatory approval to administer its Ebola treatment.
Tekmira Establishes Regulatory Framework for Emergency Use of TKM-Ebola
GlobeNewswire - Mon Sep 22, 8:53AM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that the FDA has authorized Tekmira to provide TKM-Ebola for treatment under expanded access protocols to subjects with confirmed or suspected Ebola virus infections.
Ebola-Stricken Doc Receives Experimental Drug, But Which One?
at The Street - Thu Sep 11, 1:20PM CDT
Twitter abuzz with speculation that Tekmira's experimental Ebola therapy is being used to treat patient.
Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity
at The Street - Wed Sep 10, 8:36AM CDT
The Ebola outbreak in West Africa is a public health emergency which has also captured the attention of U.S. investors (perhaps I should say traders.)
Ebola Outbreak Strikes Africa: How We're Fighting Back
Brian Orelli, The Motley Fool - Motley Fool - Mon Sep 08, 12:37PM CDT
This week, the World Health Organization announced that the Ebola outbreak in West Africa has killed more than 1,900 people. This is the largest Ebola outbreak in history, with more people dying in this outbreak than all the other outbreaks since the...
'Mad Money' Lightning Round: I Still Want to Own Freeport-McMoRan
at The Street - Sat Sep 06, 5:00AM CDT
Cramer likes Take-Two Interactive over Activision Blizzard and if you wanted Tekmira Pharmaceuticals you're too late.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Sep 05, 6:37PM CDT
Cramer is looking for bargains, and that means he'll be watching Yahoo!, Apple and Restoration Hardware next week.
J&J Ebola Vaccine Gets Funding, Development to Pick Pace - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 2:37PM CDT
Johnson & Johnson (JNJ) announced that its Ebola vaccine development process will be fast-tracked.
Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen
PR Newswire - Thu Sep 04, 7:55AM CDT
On Wednesday, September 03, 2014, the NASDAQ Composite ended at 4,572.57, down 0.56%, the Dow Jones Industrial Average finished the day 0.06% higher at 17,078.28, and the S&P 500 closed at 2,000.72, down 0.08%. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 740.75, up 0.41%, with the index advancing 6.93% in the previous three months. Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Arrowhead Research Corporation (NASDAQ: ARWR), Celgene Corporation (NASDAQ: CELG), and Amgen Inc. (NASDAQ: AMGN). Free research on these five companies can be accessed at:
BioCryst's Ebola Candidate Moving to Efficacy Study Soon - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 2:08PM CDT
BioCryst 's (BCRX) BCX4430 will be evaluated in a non-human primate study shortly.
Glaxo Up on Accelerated Ebola Vaccine Development Process - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 1:50PM CDT
Glaxo's Ebola vaccine development process has been fast-tracked by an international consortium.